

# NCTN Breast Cancer Trials Portfolio (Open as of 1/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

Neoadjuvant	Post-Neoadjuvant	Adjuvant	Metastatic
<p><b>S2212 (SCARLET)</b> TNBC T2-4/N0/M0, or T1-3/N1-2/M0</p> <p><b>S2206</b> HR+/HER2- Stage II or III</p>	<p><b>A012103 (OptimICE-PCR)</b> TNBC Early-Stage, pCR post pre-op chemo + pembrolizumab</p> <p><b>A012303 (ShortStop-HER2)</b> HER2+ Early-Stage, pCR post pre-op chemo + HER2 blockade</p>	<p><b>CCTG MA.39</b> HR+/HER2- Low risk; Node positive</p> <p><b>NRG-BR007 (DEBRA)</b> HR+/HER2- pT1(&lt;=2cm) pN0M0</p> <p><b>NRG-BR009 (OFSET)</b> HR+/HER2- pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients</p> <p><b>A012301 (LoTam)</b> HR+/HER2- Early-stage, Low molecular risk, Resected tumor ≤3cm and N0, Postmenopausal pts</p>	<p><b>EAY191 (ComboMATCH)</b></p> <p><b>Sub-study: EAY191-E5 (KRAS G12C mutation)</b></p>

## Legend by Subtype Status

Green = TNBC

Orange = HER2+  
(Any HR status)

Purple =  
HR+ and HER2-

Pink = Cross-disease trial

## NCTN Breast Cancer Trials (Open as of 1/15/2026)

Protocol Number	Phase	Protocol Title
A012103	III	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A012301	III	LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
A012303	III	ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
CCTG MA.39	III	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
NRG-BR007	III	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer (DEBRA)
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score </= 25 (OFSET)
S2206	III	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
S2212	III	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-E5	II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial